

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF  
KRAUSE, ANDREAS ET AL.

ART UNIT: 1636  
EXAMINER: DUNSTON,  
JENNIFER A

INTERNATIONAL APPLICATION NO: PCT/EP03/09292

FILED: AUGUST 21, 2003

U.S. APPLICATION NO: 10/524399

35 USC §371 DATE: FEBRUARY 11, 2005

FOR: DIAGNOSIS OF CHRONIC REJECTION

**MS: Amendment**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed:

☒ Concurrently with submission of a Request for Continued Examination (RCE)

If a fee is deemed required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134 in the name of Novartis.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

☒ Copies of the references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Novartis Pharmaceuticals Corporation  
One Health Plaza, Bldg. 101  
East Hanover, NJ 07936  
(862) 778-9308  
Date: 3/12/2010

Respectfully submitted,

  
\_\_\_\_\_  
Leslie Fischer  
Attorney for Applicant  
Reg. No. 58,393